Crinetics Pharmaceuticals Key Executives
This section highlights Crinetics Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Crinetics Pharmaceuticals
(Showing 0 of )
Crinetics Pharmaceuticals Earnings
This section highlights Crinetics Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-28 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $-0.91 | $-0.96 |
| Read Transcript | Q2 | 2024 | 2024-08-08 | $-0.86 | $-0.94 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.84 | $-0.93 |
| Read Transcript | Q4 | 2023 | 2024-02-29 | N/A | N/A |
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
$31.39
Stock Price
$2.92B
Market Cap
437
Employees
San Diego, CA
Location
Financial Statements
Access annual & quarterly financial statements for Crinetics Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.04M | $4.01M | $4.74M | $1.08M | $71.00K |
| Cost of Revenue | $- | $- | $1.39M | $1.26M | $57.00M |
| Gross Profit | $1.04M | $4.01M | $3.35M | $-184.00K | $-56.93M |
| Gross Profit Ratio | 100.00% | 100.00% | 70.68% | -17.10% | -80178.87% |
| Research and Development Expenses | $240.16M | $168.53M | $130.22M | $84.25M | $57.00M |
| General and Administrative Expenses | $99.74M | $58.09M | $42.39M | $24.52M | $18.03M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $99.74M | $58.09M | $42.39M | $24.52M | $18.03M |
| Other Expenses | $- | $- | $4.97M | $61.00K | $-71.00K |
| Operating Expenses | $339.89M | $226.62M | $172.62M | $108.78M | $74.95M |
| Cost and Expenses | $339.89M | $226.62M | $172.62M | $108.78M | $74.95M |
| Interest Income | $41.44M | $13.44M | $4.32M | $157.00K | $991.00K |
| Interest Expense | $- | $- | $4.32M | $- | $- |
| Depreciation and Amortization | $- | $1.10M | $1.39M | $1.26M | $1.23M |
| EBITDA | $-338.85M | $-221.51M | $-166.90M | $-106.78M | $-72.59M |
| EBITDA Ratio | -32613.47% | -5519.81% | -3523.00% | -9990.91% | -105567.61% |
| Operating Income | $-338.85M | $-222.61M | $-167.88M | $-107.70M | $-74.95M |
| Operating Income Ratio | -32613.47% | -5547.17% | -3544.06% | -9990.91% | -105567.61% |
| Total Other Income Expenses Net | $40.45M | $8.08M | $3.96M | $61.00K | $1.14M |
| Income Before Tax | $-298.41M | $-214.53M | $-163.92M | $-107.64M | $-73.81M |
| Income Before Tax Ratio | -28720.69% | -5345.85% | -3460.38% | -9985.25% | -103960.56% |
| Income Tax Expense | $- | $- | $-3.96M | $-922.00K | $-948.00K |
| Net Income | $-298.41M | $-214.53M | $-159.95M | $-106.72M | $-72.86M |
| Net Income Ratio | -28720.69% | -5345.85% | -3376.69% | -9899.72% | -102625.35% |
| EPS | $-3.69 | $-3.69 | $-3.08 | $-2.78 | $-2.39 |
| EPS Diluted | $-3.69 | $-3.69 | $-3.08 | $-2.78 | $-2.39 |
| Weighted Average Shares Outstanding | 80.78M | 58.07M | 51.98M | 38.44M | 30.45M |
| Weighted Average Shares Outstanding Diluted | 80.78M | 58.07M | 51.98M | 38.44M | 30.45M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $399.00K | $640.00K | $- | $346.00K | $988.00K | $2.68M | $709.00K | $458.00K | $439.00K | $3.13M | $1.08M | $- | $- | $- | $0 | $0 | $- | $71.00K |
| Cost of Revenue | $- | $- | $753.00K | $474.00K | $262.00K | $273.00K | $398.00K | $398.00K | $388.00K | $351.00K | $315.00K | $335.00K | $1.08M | $319.00K | $313.00K | $304.00K | $16.83M | $13.70M | $12.61M | $13.86M |
| Gross Profit | $- | $- | $-354.00K | $166.00K | $-262.00K | $73.00K | $590.00K | $2.28M | $321.00K | $107.00K | $124.00K | $2.80M | $1.08K | $-319.00K | $-313.00K | $-304.00K | $-16.83M | $-13.70M | $-12.61M | $-13.79M |
| Gross Profit Ratio | 0.00% | 0.00% | -88.70% | 25.90% | 0.00% | 21.10% | 59.70% | 85.10% | 45.30% | 23.40% | 28.20% | 89.30% | 0.10% | 0.00% | 0.00% | 0.00% | -23704225352112580.00% | -288278619428.62% | 0.00% | -19423.94% |
| Research and Development Expenses | $66.57M | $61.91M | $58.34M | $52.87M | $45.32M | $43.84M | $40.64M | $38.47M | $36.99M | $31.99M | $32.99M | $28.25M | $24.60M | $21.58M | $20.49M | $17.58M | $16.83M | $13.70M | $12.61M | $13.86M |
| General and Administrative Expenses | $28.18M | $25.89M | $24.84M | $20.83M | $17.08M | $15.48M | $13.34M | $12.19M | $11.27M | $11.93M | $10.49M | $8.71M | $7.36M | $6.23M | $5.60M | $5.33M | $4.96M | $4.75M | $4.32M | $3.99M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $28.18M | $25.89M | $24.84M | $20.83M | $17.08M | $15.48M | $13.34M | $12.19M | $11.27M | $11.93M | $10.49M | $8.71M | $7.36M | $6.23M | $5.60M | $5.33M | $4.96M | $4.75M | $4.32M | $3.99M |
| Other Expenses | $- | $- | $- | $-251.00K | $40.00K | $2.52M | $-91.00K | $1.98M | $2.56M | $29.00K | $-81.00K | $17.00K | $94.00K | $-68.00K | $-29.00K | $-13.00K | $150.00K | $9.00K | $178.00K | $-134.00K |
| Operating Expenses | $94.75M | $87.80M | $83.18M | $73.69M | $62.40M | $59.32M | $53.98M | $50.66M | $48.27M | $43.91M | $43.48M | $36.96M | $31.97M | $27.81M | $26.09M | $22.92M | $21.79M | $18.45M | $16.93M | $17.78M |
| Cost and Expenses | $94.75M | $87.80M | $83.18M | $74.17M | $62.66M | $59.32M | $53.98M | $50.66M | $48.27M | $43.91M | $43.48M | $36.96M | $31.97M | $27.81M | $26.09M | $22.92M | $21.79M | $18.45M | $16.93M | $17.78M |
| Interest Income | $14.37M | $11.01M | $8.74M | $7.32M | $6.72M | $2.57M | $2.11M | $2.04M | $1.90M | $1.50M | $720.00K | $193.00K | $80.00K | $24.00K | $23.00K | $30.00K | $53.00K | $122.00K | $260.00K | $556.00K |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $1.90M | $1.50M | $720.00K | $193.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $788.00K | $770.00K | $753.00K | $474.00K | $262.00K | $273.00K | $398.00K | $398.00K | $388.00K | $351.00K | $315.00K | $335.00K | $326.00K | $319.00K | $313.00K | $304.00K | $225.00K | $244.00K | $244.00K | $235.00K |
| EBITDA | $-93.96M | $-87.03M | $-82.03M | $-73.06M | $-62.40M | $-58.70M | $-52.72M | $-47.70M | $-47.28M | $-43.21M | $-42.83M | $-33.59M | $-30.65M | $-27.57M | $-25.86M | $-22.69M | $-21.57M | $-18.21M | $-16.68M | $-17.55M |
| EBITDA Ratio | 0.00% | 0.00% | -20558.90% | -11415.00% | 0.00% | -16966.00% | -5335.53% | -1780.00% | -6707.48% | -9433.62% | -9763.33% | -1072.72% | -2865.31% | 0.00% | 0.00% | 0.00% | -30691549295774656.00% | -383143939393.94% | 0.00% | -24714.08% |
| Operating Income | $-94.75M | $-87.80M | $-82.78M | $-74.17M | $-62.66M | $-58.98M | $-52.99M | $-47.98M | $-47.56M | $-43.45M | $-43.05M | $-33.83M | $-30.89M | $-27.81M | $-26.09M | $-22.92M | $-21.79M | $-18.45M | $-16.93M | $-17.78M |
| Operating Income Ratio | 0.00% | 0.00% | -20747.62% | -11588.91% | 0.00% | -17045.38% | -5363.87% | -1790.89% | -6707.48% | -9487.77% | -9805.24% | -1080.39% | -2865.31% | 0.00% | 0.00% | 0.00% | -30691549295774656.00% | -388278619528.62% | 0.00% | -25045.07% |
| Total Other Income Expenses Net | $14.15M | $10.97M | $8.73M | $6.60M | $2.56M | $1.52M | $2.02M | $1.98M | $2.56M | $1.53M | $670.00K | $-800.00K | $94.00K | $-44.00K | $-6.00K | $17.00K | $150.00K | $131.00K | $438.00K | $422.00K |
| Income Before Tax | $-80.59M | $-76.83M | $-74.06M | $-66.93M | $-60.10M | $-57.46M | $-50.98M | $-45.99M | $-44.99M | $-41.92M | $-42.38M | $-34.63M | $-30.79M | $-27.85M | $-26.09M | $-22.90M | $-21.64M | $-18.32M | $-16.49M | $-17.36M |
| Income Before Tax Ratio | 0.00% | 0.00% | -18560.15% | -10457.81% | 0.00% | -16606.36% | -5159.82% | -1716.87% | -6345.70% | -9153.93% | -9652.62% | -1105.94% | -2856.59% | 0.00% | 0.00% | 0.00% | -30480281690140848.00% | -385521885521.89% | 0.00% | -24450.70% |
| Income Tax Expense | $- | $- | $- | $-1 | $218.19K | $-273.00K | $-2.11M | $-1.98M | $-2.56M | $-1.53M | $-670.00K | $800.00K | $-107.63M | $-24.00K | $-23.00K | $-30.00K | $-225.00K | $-122.00K | $-260.00K | $-556.00K |
| Net Income | $-80.59M | $-76.83M | $-74.06M | $-66.93M | $-60.10M | $-57.46M | $-50.98M | $-44.01M | $-42.43M | $-40.40M | $-41.70M | $-35.43M | $-30.79M | $-27.85M | $-26.09M | $-22.90M | $-21.64M | $-18.32M | $-16.49M | $-17.36M |
| Net Income Ratio | 0.00% | 0.00% | -18560.15% | -10457.81% | 0.00% | -16606.36% | -5159.82% | -1642.85% | -5983.92% | -8820.09% | -9500.00% | -1131.49% | -2856.59% | 0.00% | 0.00% | 0.00% | -30480281690140848.00% | -385521885521.89% | 0.00% | -24450.70% |
| EPS | $-0.88 | $-0.96 | $-0.94 | $-0.93 | $-0.90 | $-1.01 | $-0.94 | $-0.82 | $-0.79 | $-0.75 | $-0.79 | $-0.75 | $-0.68 | $-0.73 | $-0.70 | $-0.69 | $-0.66 | $-0.56 | $-0.53 | $-0.71 |
| EPS Diluted | $-0.88 | $-0.96 | $-0.94 | $-0.93 | $-0.90 | $-1.01 | $-0.94 | $-0.82 | $-0.79 | $-0.75 | $-0.79 | $-0.74 | $-0.68 | $-0.73 | $-0.70 | $-0.69 | $-0.66 | $-0.56 | $-0.53 | $-0.71 |
| Weighted Average Shares Outstanding | 91.49M | 80.09M | 79.01M | 72.29M | 67.15M | 56.81M | 54.27M | 53.91M | 53.84M | 53.77M | 52.52M | 47.43M | 45.23M | 38.31M | 37.06M | 33.01M | 32.95M | 32.89M | 31.41M | 24.49M |
| Weighted Average Shares Outstanding Diluted | 91.49M | 80.09M | 79.01M | 72.29M | 67.15M | 56.81M | 54.27M | 53.91M | 53.84M | 53.77M | 52.52M | 47.71M | 45.23M | 38.31M | 37.06M | 33.01M | 32.95M | 32.89M | 31.41M | 24.49M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $264.55M | $54.90M | $32.67M | $200.69M | $93.09M |
| Short Term Investments | $1.09B | $503.66M | $301.75M | $133.01M | $77.79M |
| Cash and Short Term Investments | $1.35B | $558.55M | $334.43M | $333.71M | $170.88M |
| Net Receivables | $- | $9.35M | $- | $2.03M | $1.83M |
| Inventory | $- | $- | $- | $8.07M | $-1.83M |
| Other Current Assets | $21.32M | $6.25M | $10.76M | $8.07M | $4.78M |
| Total Current Assets | $1.38B | $574.15M | $345.18M | $344.72M | $177.49M |
| Property Plant Equipment Net | $55.58M | $57.43M | $4.99M | $4.72M | $5.41M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $1.77M | $1.97M | $1.01M | $500.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.63M | $2.00M | $37.00K | $568.00K | $40.00K |
| Total Non-Current Assets | $59.20M | $61.20M | $6.99M | $6.29M | $5.95M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.43B | $635.35M | $352.18M | $351.01M | $183.44M |
| Account Payables | $5.85M | $6.55M | $6.88M | $3.42M | $3.49M |
| Short Term Debt | $7.15M | $4.17M | $1.05M | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $2.18M | $2.06M | $2.24M | $-939.00K | $-835.00K |
| Other Current Liabilities | $44.50M | $31.16M | $17.55M | $12.57M | $7.00M |
| Total Current Liabilities | $59.68M | $43.94M | $27.72M | $15.99M | $10.49M |
| Long Term Debt | $44.57M | $47.55M | $2.02M | $3.07M | $4.01M |
| Deferred Revenue Non-Current | $- | $4.75M | $6.10M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $-6.10M | $- | $- |
| Other Non-Current Liabilities | $5.53M | $- | $- | $2.00K | $23.00K |
| Total Non-Current Liabilities | $50.10M | $52.30M | $8.12M | $3.08M | $4.04M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $109.79M | $96.25M | $35.85M | $19.07M | $14.53M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.28B | $1.19B | $759.43M | $607.58M | $336.51M |
| Retained Earnings | $-952.11M | $-653.70M | $-439.17M | $-275.25M | $-167.61M |
| Accumulated Other Comprehensive Income Loss | $963.00K | $977.00K | $-3.93M | $-382.00K | $25.00K |
| Other Total Stockholders Equity | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $1.32B | $539.11M | $-439.17M | $-275.25M | $-167.61M |
| Total Equity | $1.32B | $539.11M | $-439.17M | $-275.25M | $-167.61M |
| Total Liabilities and Stockholders Equity | $1.43B | $635.35M | $-403.32M | $-256.18M | $-153.09M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.43B | $635.35M | $-403.32M | $-256.18M | $-153.09M |
| Total Investments | $1.09B | $505.43M | $301.75M | $134.02M | $77.79M |
| Total Debt | $51.72M | $51.73M | $2.02M | $3.07M | $4.01M |
| Net Debt | $-212.82M | $-3.17M | $-30.65M | $-197.62M | $-89.07M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $264.55M | $317.27M | $302.16M | $395.92M | $54.90M | $142.79M | $39.55M | $41.19M | $32.67M | $30.91M | $62.29M | $145.55M | $200.69M | $161.54M | $178.77M | $105.58M | $93.09M | $117.82M | $160.81M | $50.92M |
| Short Term Investments | $1.09B | $545.40M | $560.79M | $505.04M | $503.66M | $411.86M | $224.98M | $254.93M | $301.75M | $337.45M | $346.21M | $174.18M | $133.01M | $31.79M | $24.99M | $45.09M | $77.79M | $69.00M | $44.35M | $61.88M |
| Cash and Short Term Investments | $1.35B | $862.67M | $862.95M | $900.96M | $558.55M | $554.65M | $264.53M | $296.12M | $334.43M | $368.36M | $408.51M | $319.73M | $333.71M | $193.32M | $203.76M | $150.66M | $170.88M | $186.82M | $205.16M | $112.80M |
| Net Receivables | $8.47M | $7.03M | $5.10M | $9.44M | $9.35M | $11.64M | $11.82M | $2.35M | $- | $2.35M | $2.11M | $1.54M | $2.03M | $1.04M | $1.04M | $857.00K | $1.83M | $1.77M | $1.52M | $1.22M |
| Inventory | $- | $- | $- | $- | $- | $-11.64M | $15.14M | $-2.35M | $- | $5.96M | $4.04M | $5.36M | $-2.03M | $- | $- | $- | $-1.83M | $- | $- | $- |
| Other Current Assets | $12.85M | $7.89M | $6.72M | $6.83M | $6.25M | $9.47M | $17.90M | $3.65M | $10.76M | $7.62M | $5.67M | $6.98M | $8.07M | $2.22M | $1.29M | $1.35M | $4.78M | $1.68M | $753.00K | $775.00K |
| Total Current Assets | $1.38B | $877.59M | $874.78M | $917.23M | $574.15M | $575.76M | $284.81M | $305.40M | $345.18M | $378.32M | $416.29M | $328.25M | $344.72M | $203.97M | $211.35M | $157.80M | $177.49M | $194.12M | $210.61M | $117.17M |
| Property Plant Equipment Net | $55.58M | $55.98M | $57.26M | $57.62M | $57.43M | $57.81M | $4.47M | $4.64M | $4.99M | $5.16M | $4.85M | $4.47M | $4.72M | $4.89M | $5.07M | $5.25M | $5.41M | $5.70M | $6.01M | $6.22M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $2.00M | $1.30M | $1.77M | $5.97M | $1.97M | $1.97M | $1.97M | $1.40M | $346.21M | $568.00K | $1.01M | $500.00K | $500.00K | $500.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.63M | $3.81M | $1.50M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $37.00K | $- | $-345.61M | $- | $568.00K | $- | $- | $- | $540.00K | $500.00K | $500.00K | $500.00K |
| Total Non-Current Assets | $59.20M | $59.79M | $60.76M | $60.92M | $61.20M | $65.78M | $8.44M | $8.61M | $6.99M | $6.56M | $5.45M | $5.04M | $6.29M | $5.39M | $5.57M | $5.75M | $5.95M | $6.20M | $6.51M | $6.72M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.43B | $937.37M | $935.53M | $978.15M | $635.35M | $641.54M | $293.25M | $314.01M | $352.18M | $384.88M | $421.73M | $333.29M | $351.01M | $209.36M | $216.93M | $163.55M | $183.44M | $200.32M | $217.12M | $123.88M |
| Account Payables | $5.85M | $4.94M | $8.87M | $10.76M | $6.55M | $5.84M | $4.84M | $5.89M | $6.88M | $5.88M | $9.04M | $4.73M | $3.42M | $3.05M | $3.75M | $2.91M | $3.49M | $2.59M | $2.56M | $4.30M |
| Short Term Debt | $7.15M | $7.41M | $14.89M | $11.58M | $4.17M | $7.98M | $2.22M | $2.16M | $1.05M | $2.04M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $2.18M | $1.69M | $2.56M | $2.46M | $2.06M | $1.66M | $2.08M | $2.12M | $2.24M | $2.32M | $2.54M | $2.71M | $-939.00K | $-912.00K | $-886.00K | $-860.00K | $- | $- | $- | $- |
| Other Current Liabilities | $44.50M | $39.52M | $28.05M | $26.96M | $31.16M | $24.98M | $23.47M | $16.15M | $17.55M | $14.31M | $14.53M | $12.82M | $12.57M | $9.39M | $8.17M | $7.35M | $7.00M | $6.24M | $7.31M | $6.46M |
| Total Current Liabilities | $59.68M | $53.56M | $54.38M | $51.77M | $43.94M | $40.46M | $32.61M | $26.32M | $27.72M | $24.56M | $26.11M | $20.26M | $15.99M | $12.44M | $11.92M | $10.26M | $10.49M | $8.83M | $9.87M | $10.76M |
| Long Term Debt | $44.57M | $45.13M | $45.87M | $46.71M | $47.55M | $48.18M | $1.46M | $1.74M | $2.02M | $2.30M | $2.56M | $2.82M | $3.07M | $3.32M | $3.56M | $3.79M | $4.01M | $4.23M | $4.44M | $4.65M |
| Deferred Revenue Non-Current | $4.70M | $- | $4.32M | $4.74M | $4.75M | $5.14M | $5.07M | $5.62M | $6.10M | $6.65M | $6.89M | $7.16M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $-47.55M | $-5.14M | $-5.07M | $-5.62M | $-6.10M | $-6.65M | $-6.89M | $-7.16M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $829.00K | $5.71M | $202.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.00K | $7.00K | $12.00K | $18.00K | $23.00K | $28.00K | $34.00K | $39.00K |
| Total Non-Current Liabilities | $50.10M | $50.83M | $50.40M | $51.45M | $52.30M | $53.33M | $6.53M | $7.36M | $8.12M | $8.95M | $9.45M | $9.98M | $3.08M | $3.33M | $3.57M | $3.81M | $4.04M | $4.26M | $4.48M | $4.69M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $109.79M | $104.39M | $104.77M | $103.22M | $96.25M | $93.79M | $39.14M | $33.68M | $35.85M | $33.51M | $35.57M | $30.24M | $19.07M | $15.77M | $15.49M | $14.07M | $14.53M | $13.10M | $14.35M | $15.45M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.28B | $1.70B | $1.63B | $1.60B | $1.19B | $1.14B | $791.97M | $768.01M | $759.43M | $750.56M | $742.04M | $615.12M | $607.58M | $438.06M | $418.04M | $339.98M | $336.51M | $333.15M | $330.30M | $219.43M |
| Retained Earnings | $-952.11M | $-871.51M | $-794.69M | $-720.63M | $-653.70M | $-593.61M | $-536.15M | $-485.17M | $-439.17M | $-394.18M | $-352.26M | $-309.88M | $-275.25M | $-244.46M | $-216.61M | $-190.51M | $-167.61M | $-145.97M | $-127.65M | $-111.16M |
| Accumulated Other Comprehensive Income Loss | $963.00K | $2.04M | $-190.00K | $150.00K | $977.00K | $-865.00K | $-1.71M | $-2.51M | $-3.93M | $-5.01M | $-3.62M | $-2.19M | $-382.00K | $-12.00K | $10.00K | $19.00K | $25.00K | $44.00K | $127.00K | $167.00K |
| Other Total Stockholders Equity | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $1.32B | $832.98M | $830.76M | $874.93M | $539.11M | $-593.61M | $254.12M | $-485.17M | $-439.17M | $351.37M | $386.17M | $303.04M | $-275.25M | $193.59M | $201.44M | $149.48M | $-167.61M | $187.22M | $202.77M | $108.44M |
| Total Equity | $1.32B | $832.98M | $830.76M | $874.93M | $539.11M | $-593.61M | $254.12M | $-485.17M | $-439.17M | $351.37M | $386.17M | $303.04M | $-275.25M | $193.59M | $201.44M | $149.48M | $-167.61M | $187.22M | $202.77M | $108.44M |
| Total Liabilities and Stockholders Equity | $1.43B | $937.37M | $935.53M | $978.15M | $635.35M | $-499.82M | $293.25M | $-451.49M | $-403.32M | $384.88M | $421.73M | $333.29M | $-256.18M | $209.36M | $216.93M | $163.55M | $-153.09M | $200.32M | $217.12M | $123.88M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.43B | $937.37M | $935.53M | $978.15M | $635.35M | $-499.82M | $293.25M | $-451.49M | $-403.32M | $384.88M | $421.73M | $333.29M | $-256.18M | $209.36M | $216.93M | $163.55M | $-153.09M | $200.32M | $217.12M | $123.88M |
| Total Investments | $1.09B | $545.40M | $562.09M | $506.34M | $505.43M | $411.86M | $224.98M | $254.93M | $301.75M | $337.45M | $692.43M | $174.18M | $133.01M | $31.79M | $24.99M | $45.09M | $77.79M | $69.00M | $44.35M | $61.88M |
| Total Debt | $51.72M | $52.54M | $53.32M | $52.50M | $51.73M | $52.17M | $2.56M | $2.82M | $2.02M | $3.32M | $2.56M | $2.82M | $3.07M | $3.32M | $3.56M | $3.79M | $4.01M | $4.23M | $4.44M | $4.65M |
| Net Debt | $-212.82M | $-264.73M | $-248.84M | $-343.42M | $-3.17M | $-90.62M | $-36.99M | $-38.37M | $-30.65M | $-27.59M | $-59.73M | $-142.73M | $-197.62M | $-158.21M | $-175.21M | $-101.79M | $-89.07M | $-113.59M | $-156.37M | $-46.27M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-298.41M | $-214.53M | $-163.92M | $-107.64M | $-73.81M |
| Depreciation and Amortization | $2.79M | $1.10M | $983.00K | $922.00K | $948.00K |
| Deferred Income Tax | $- | $-28.48M | $- | $422.00K | $-227.00K |
| Stock Based Compensation | $69.39M | $40.94M | $28.27M | $17.35M | $10.43M |
| Change in Working Capital | $11.63M | $8.04M | $18.61M | $1.10M | $376.00K |
| Accounts Receivables | $17.54M | $14.65M | $10.99M | $6.29M | $2.72M |
| Inventory | $- | $- | $- | $-6.29M | $-2.72M |
| Accounts Payables | $- | $- | $10.99M | $6.29M | $2.72M |
| Other Working Capital | $-5.91M | $-6.60M | $-3.38M | $-5.20M | $-2.35M |
| Other Non Cash Items | $-11.37M | $26.63M | $850.00K | $-739.00K | $261.00K |
| Net Cash Provided by Operating Activities | $-225.97M | $-166.31M | $-115.20M | $-88.59M | $-62.03M |
| Investments in Property Plant and Equipment | $-3.84M | $-4.69M | $-1.66M | $-436.00K | $-186.00K |
| Acquisitions Net | $- | $195.72M | $34.00K | $422.00K | $-227.00K |
| Purchases of Investments | $-1.16B | $-532.86M | $-329.82M | $-125.40M | $-135.59M |
| Sales Maturities of Investments | $575.80M | $337.13M | $157.49M | $69.36M | $136.00M |
| Other Investing Activities | $14.93M | $-195.72M | $-34.00K | $-422.00K | $227.00K |
| Net Cash Used for Investing Activities | $-574.82M | $-200.41M | $-173.98M | $-56.48M | $217.00K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $970.05M | $369.02M | $117.24M | $249.54M | $114.28M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $40.39M | $19.93M | $4.72M | $3.14M | $288.00K |
| Net Cash Used Provided by Financing Activities | $1.01B | $388.94M | $121.96M | $252.68M | $114.57M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $209.65M | $22.22M | $-167.22M | $107.61M | $52.76M |
| Cash at End of Period | $265.85M | $56.20M | $33.97M | $201.19M | $93.59M |
| Cash at Beginning of Period | $56.20M | $33.97M | $201.19M | $93.59M | $40.83M |
| Operating Cash Flow | $-225.97M | $-166.31M | $-115.20M | $-88.59M | $-62.03M |
| Capital Expenditure | $-3.84M | $-4.69M | $-1.66M | $-436.00K | $-186.00K |
| Free Cash Flow | $-229.81M | $-171.00M | $-116.86M | $-89.02M | $-62.21M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-80.59M | $-76.83M | $-74.06M | $-66.93M | $-60.10M | $-57.46M | $-50.98M | $-45.99M | $-44.99M | $-41.92M | $-42.38M | $-34.63M | $-30.79M | $-27.85M | $-26.09M | $-22.90M | $-21.64M | $-18.32M | $-16.49M | $-17.36M |
| Depreciation and Amortization | $788.00K | $770.00K | $753.00K | $474.00K | $262.00K | $273.00K | $280.00K | $283.00K | $280.00K | $248.00K | $215.00K | $240.00K | $235.00K | $233.00K | $230.00K | $224.00K | $225.00K | $244.00K | $244.00K | $235.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $-7.21M | $-905.00K | $- | $- | $- | $- | $- | $186.00K | $66.00K | $87.00K | $83.00K | $66.00K | $- | $-113.00K | $-180.00K |
| Stock Based Compensation | $18.84M | $18.15M | $18.94M | $13.45M | $11.62M | $11.05M | $10.18M | $8.10M | $7.95M | $7.43M | $7.13M | $5.75M | $5.16M | $4.55M | $4.23M | $3.41M | $2.97M | $2.78M | $2.53M | $2.15M |
| Change in Working Capital | $-308.00K | $-14.10M | $11.40M | $2.69M | $8.30M | $4.85M | $-4.42M | $-687.00K | $2.37M | $-4.21M | $6.79M | $13.66M | $3.31M | $-2.77M | $1.51M | $-959.00K | $2.37M | $-2.79M | $-2.08M | $2.88M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $7.23M | $1.31M | $4.19M | $4.38M | $7.42M | $-1.34M | $2.75M | $-1.33M | $8.24M | $1.53M | $3.90M | $494.00K | $2.17M | $-271.00K | $1.92M | $-752.00K | $-831.00K | $2.39M |
| Other Working Capital | $-308.00K | $-14.10M | $4.17M | $1.39M | $4.11M | $470.00K | $-11.84M | $658.00K | $-385.00K | $-2.88M | $-1.45M | $12.13M | $-586.00K | $-3.27M | $-658.00K | $-688.00K | $451.00K | $-2.04M | $-1.25M | $491.00K |
| Other Non Cash Items | $-3.40M | $9.18M | $-2.66M | $10.55M | $9.35M | $7.15M | $118.00K | $-2.42M | $-812.00K | $-29.00K | $264.00K | $1.43M | $-996.00K | $95.00K | $82.00K | $80.00K | $75.00K | $78.00K | $62.00K | $46.00K |
| Net Cash Provided by Operating Activities | $-64.67M | $-62.82M | $-45.62M | $-52.86M | $-38.52M | $-41.34M | $-45.73M | $-40.72M | $-35.21M | $-38.48M | $-27.98M | $-13.54M | $-22.90M | $-25.67M | $-19.95M | $-20.07M | $-15.94M | $-18.00M | $-15.86M | $-12.23M |
| Investments in Property Plant and Equipment | $-1.03M | $-528.00K | $-955.00K | $-1.33M | $-935.00K | $-3.50M | $-237.00K | $-16.00K | $-274.00K | $-682.00K | $-613.00K | $-87.00K | $-18.00K | $-140.00K | $-162.00K | $-116.00K | $-17.00K | $-97.00K | $-12.00K | $-60.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $189.80M | $-31.67M | $-530.00K | $34.00K | $-7.50M | $173.66M | $322.00K | $101.80M | $- | $- | $83.00K | $-630.00K | $- | $- | $-180.00K |
| Purchases of Investments | $-725.03M | $-140.78M | $-191.99M | $-99.74M | $-173.05M | $-277.64M | $-59.49M | $-22.67M | $-33.56M | $-48.68M | $-192.56M | $-55.02M | $-102.02M | $-20.84M | $- | $-2.54M | $-21.83M | $-43.66M | $-47.22M | $-22.89M |
| Sales Maturities of Investments | $183.97M | $151.15M | $139.30M | $101.38M | $86.68M | $87.84M | $91.17M | $71.44M | $70.69M | $56.19M | $18.90M | $11.72M | $244.00K | $13.96M | $20.00M | $35.15M | $12.96M | $18.93M | $64.83M | $39.28M |
| Other Investing Activities | $- | $10.77M | $- | $1.64M | $-86.37M | $-189.80M | $31.67M | $530.00K | $-34.00K | $7.50M | $-173.66M | $-322.00K | $-101.80M | $-6.88M | $20.00M | $-83.00K | $630.00K | $-24.73M | $17.61M | $180.00K |
| Net Cash Used for Investing Activities | $-542.09M | $20.60M | $-53.64M | $309.00K | $-87.31M | $-193.30M | $31.44M | $48.76M | $36.85M | $6.82M | $-174.27M | $-43.38M | $-101.80M | $-7.03M | $19.84M | $32.50M | $-8.89M | $-24.83M | $17.60M | $16.34M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $544.50M | $46.65M | $-4.31M | $383.21M | $28.75M | $328.96M | $11.31M | $484.00K | $115.00K | $-13.00K | $118.99M | $1.78M | $162.01M | $14.98M | $72.56M | $57.00K | $-72.44M | $-158.00K | $108.08M | $6.43M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $9.54M | $10.68M | $5.50M | $10.36M | $9.17M | $8.92M | $1.35M | $484.00K | $115.00K | $1.08M | $118.99M | $1.78M | $1.85M | $487.00K | $745.00K | $57.00K | $97.00K | $64.00K | $72.00K | $55.00K |
| Net Cash Used Provided by Financing Activities | $554.04M | $57.33M | $5.50M | $393.57M | $37.92M | $337.88M | $12.66M | $484.00K | $115.00K | $1.08M | $118.99M | $1.78M | $163.86M | $15.46M | $73.30M | $57.00K | $97.00K | $-158.00K | $108.15M | $6.48M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-52.72M | $15.11M | $-93.76M | $341.03M | $-87.90M | $103.24M | $-1.64M | $8.52M | $1.76M | $-30.58M | $-83.25M | $-55.15M | $39.16M | $-17.23M | $73.19M | $12.49M | $-24.73M | $-42.99M | $109.90M | $10.59M |
| Cash at End of Period | $265.85M | $318.57M | $302.16M | $395.92M | $54.90M | $142.79M | $40.85M | $42.49M | $33.97M | $32.21M | $62.79M | $146.05M | $201.19M | $162.04M | $179.27M | $106.08M | $93.59M | $118.32M | $161.31M | $51.42M |
| Cash at Beginning of Period | $318.57M | $303.46M | $395.92M | $54.90M | $142.79M | $39.55M | $42.49M | $33.97M | $32.21M | $62.79M | $146.05M | $201.19M | $162.04M | $179.27M | $106.08M | $93.59M | $118.32M | $161.31M | $51.42M | $40.83M |
| Operating Cash Flow | $-64.67M | $-62.82M | $-45.62M | $-52.86M | $-38.52M | $-41.34M | $-45.73M | $-40.72M | $-35.21M | $-38.48M | $-27.98M | $-13.54M | $-22.90M | $-25.67M | $-19.95M | $-20.07M | $-15.94M | $-18.00M | $-15.86M | $-12.23M |
| Capital Expenditure | $-1.03M | $-528.00K | $-955.00K | $-1.33M | $-935.00K | $-3.50M | $-237.00K | $-16.00K | $-274.00K | $-682.00K | $-613.00K | $-87.00K | $-18.00K | $-140.00K | $-162.00K | $-116.00K | $-17.00K | $-97.00K | $-12.00K | $-60.00K |
| Free Cash Flow | $-65.70M | $-63.35M | $-46.57M | $-54.19M | $-39.45M | $-44.84M | $-45.97M | $-40.73M | $-35.48M | $-39.16M | $-28.59M | $-13.63M | $-22.92M | $-25.81M | $-20.11M | $-20.18M | $-15.96M | $-18.10M | $-15.87M | $-12.29M |
Crinetics Pharmaceuticals Dividends
Explore Crinetics Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Crinetics Pharmaceuticals News
Read the latest news about Crinetics Pharmaceuticals, including recent articles, headlines, and updates.
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA
Crinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over injectable somatostatin analogs, achieving high IGF-1 control rates in pretreated patients. Positive Phase 2 data for Paltusotine in carcinoid syndrome and Atumelnant in congenital adrenal hyperplasia highlight CRNX's expanding therapeutic potential.
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterized by consistently elevated levels of growth hormone. The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). Additionally, the EMA on February 27, 2025 granted paltusotine Orphan Drug Designation (ODD) for the treatment of acromegaly.
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee; and granted an aggregate of 40,775 restricted stock unit (“RSU”) awards to sixteen new non-executive employees and 52,000 to one new executive employee; in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Isabel Kalofonos - Chief Commercial Officer Dana Pizzuti - Chief Medical and Development Officer Steve Betz - Founder & Chief Scientific Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Tyler Van Buren - TD Cowen Joe Schwartz - Leerink Partners Jessica Fye - J.P. Morgan Gavin Clark-Gartner - Evercore ISI Catherine Okoukoni - Citizens Dennis Ding - Jefferies Catherine Novack - Jones Trading Rohan Mathur - Oppenheimer Andy Chen - Wolfe Research Charles Moore - Baird Operator Good afternoon, everyone.
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and Additional Early-Stage Trials from Development Pipeline in 2025 Strong Financial Position with $1.4B Cash with Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience.
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL.
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit (“RSU”) awards to 14 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock to sixteen new non-executive employees and 100,000 to one new executive employee under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.m. Pacific Time.
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement.
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Marc Wilson - Chief Financial Officer Dana Pizzuti - Chief Medical and Development Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Cory Jubinville - LifeSci Capital Jessica Fye - J.P. Morgan Jeff Hung - Morgan Stanley Charlie Moore - Baird Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Douglas Tsao - H.C.
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform at North American Neuroendocrine Tumor Society (NANETS) Total of Four New Drug Candidates in IND-Enabling Preclinical Studies Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the third quarter ended September 30, 2024.
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common stock to twenty-seven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500.0 million. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock. The offering is expected to close on or about October 10, 2024, subject to the satisfaction of customary closing conditions.
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of common stock. All of the shares to be sold in the proposed offering are to be sold by Crinetics. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist in development for the proposed treatment and long-term maintenance therapy of acromegaly.
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 120,200 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September.
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 103,900 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head of Investor Relations Scott Struthers - Founder and Chief Executive Officer Dana Pizzuti - Chief Medical and Development Officer Jim Hassard - Chief Commercial Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Jessica Fye - JPMorgan Yasmeen Rahimi - Piper Sandler Jeff Hung - Morgan Stanley Dennis Ding - Jefferies Joseph Schwartz - Leerink Partners Gavin Clark-Gartner - Evercore ISI Charles Moore - Baird Catherine Novack - Jones Research Jon Wolleben - Citizens JMP Leland Gershell - Oppenheimer Douglas Tsao - H.C. Wainwright Cory Jubinville - LifeSci Capital Operator Good day everyone, and welcome to the Crinetics Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CRNX.